Stevanato Group Introduces Deora™, a Pen Injector for Subcutaneous Delivery in Diabetes and Weight Management
PIOMBINO DESE, Italy--( BUSINESS WIRE)-- Stevanato Group S.p.A. (NYSE: STVN), a leading global provider of drug containment, drug delivery, and diagnostic solutions for the pharmaceutical, biotechnology, and life sciences industries, today introduced Deora™, a new proprietary pen injector platform targeting incretin-based therapies, as well as supporting other originator and biosimilar drug development programs.
Stevanato Group targets GLP-1 and obesity markets with Deora™, a platform designed to simplify fixed-dose delivery, reduce use error and support scalable manufacturing, helping pharma partners advance early development and prepare for future scaleup.
Deora™ is a multi-use, fixed-dose pen injector featuring a simple pull-push mechanism for dose setting and delivery: the user pulls to set the dose, then pushes to inject. This intuitive sequence eliminates the need for manual dose selection, reducing common sources of use error and supporting consistent drug delivery across multiple administrations. The platform is compatible with standard 1.5 mL and 3 mL cartridges and accommodates fixed-dose volumes up to 0.75 mL.
“With Deora™, we are broadening our product offering in therapeutic areas experiencing strong global demand and favorable market momentum,” said Michele Monico, President of Drug Delivery Systems and In Vitro Diagnostics at Stevanato Group. "We believe there is space for a simple, multi-use device that enhances the patient experience while simultaneously reducing the pressure on supply chain scale-up. Our belief has been supported by early customer interest, and we are providing our pharmaceutical partners with evaluation units to support early-stage testing and development activities.”
The device architecture provides flexibility across multiple fixed-dose configurations while minimizing the need for design changes across variants. In addition, it is designed to integrate seamlessly into existing supply chains, enabling efficient industrialization and scalable manufacturing.
“Deora™ further expands Stevanato Group’s proprietary portfolio of drug delivery devices, providing a solution designed for multi-dose therapies requiring consistent administration and ease of use in a familiar pen format,” added Michele Monico. “Customers can now choose from different hand-held device platforms – Alina®, Aidaptus®, and Deora™ – to address a broad range of therapeutic needs.”
Deora™ leverages Stevanato Group’s established manufacturing capabilities, with production aligned to support future commercialization. Drawing on its end-to-end expertise across glass manufacturing, analytical services, and device engineering, Stevanato Group offers fully integrated solutions that can simplify development for pharmaceutical partners.
Together, these characteristics position Deora™ as a platform intended to support partners as they advance early development programs and prepare for future scale-up.
About Stevanato Group
Founded in 1949, Stevanato Group is a leading global provider of drug containment, drug delivery and diagnostic solutions to the pharmaceutical, biotechnology and life sciences industries. The Group delivers an integrated, end-to-end portfolio of products, processes and services that address customer needs across the entire drug life cycle at each of the development, clinical and commercial stages. Stevanato Group’s core capabilities in scientific research and development, its commitment to technical innovation and its engineering excellence are central to its ability to offer value added solutions to clients. To learn more, visit: www.stevanatogroup.com.
Forward-Looking Statements
This press release may include forward-looking statements. The words “strong”, “experiencing”, “believe”, “are providing”, “position”, “advance”, “intended”, “prepare”, “future”, and similar expressions (or their negative) identify certain of these forward-looking statements. These forward-looking statements are statements regarding the Company's intentions, beliefs or current expectations concerning, among other things, the investments the Company expects to receive, the expansion of manufacturing capacity, the Company’s plans regarding its presence in the U.S. market, business strategies, the Company’s capacity to meet future market demands and support preparedness for future public health emergencies, and results of operations. The forward-looking statements in this press release are based on numerous assumptions regarding the Company’s present and future business strategies and the environment in which the Company will operate in the future. Forward-looking statements involve inherent known and unknown risks, uncertainties and contingencies because they relate to events and depend on circumstances that may or may not occur in the future and may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by such forward-looking statements. Many of these risks and uncertainties relate to factors that are beyond the Company's ability to control or estimate precisely, such as future market conditions, currency fluctuations, the behavior of other market participants, the actions of regulators and other factors such as the Company's ability to continue to obtain financing to meet its liquidity needs, changes in the political, social and regulatory framework in which the Company operates or in economic or technological trends or conditions. Readers should therefore not place undue reliance on these statements, particularly not in connection with any contract or investment decision. Except as required by law, the company assumes no obligation to update any such forward-looking statements.